About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Oncology Discovery Research
›
top-articles
Oncology Discovery Research
11
(top 5%)
papers
769
(top 2%)
citations
9
(top 2%)
h
-index
9
(top 5%)
g
-index
12
all documents
820
doc citations
322
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
Journal of Biological Chemistry
2012
171
2
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Molecular Cancer Therapeutics
2015
144
3
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Molecular Cancer Therapeutics
2014
126
4
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3
PLoS ONE
2015
83
5
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Molecular Cancer Therapeutics
2018
77
6
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Oncotarget
2017
56
7
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Scientific Reports
2019
54
8
PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma
PLoS Genetics
2016
41
9
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
BRAF
or
KRAS
Mutations
Clinical Cancer Research
2017
40
10
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
2015
27
11
Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer
2016
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.